According to a recent editorial in the Annals of Internal Medicine, the prostate-specific antigen (PSA) blood test can prove valuable in reducing a man's risk of dying from prostate cancer, but problems persist in implementing the test.

Early tumor detection using the prostate-specific antigen (PSA) blood test lowers a man's risk of prostate cancer death by 25 percent to 32 percent, according to the journal's analysis of two major trials of PSA testing.

To help clear up some of the confusion, view a presentation by UT Southwestern radiologist Daniel Costa, M.D., on elevated PSA and prostate MR.

Coming in October, an online CME presentation by UT Southwestern urologist Claus Roehrborn entitled, "To Order or Not to Order the Prostate-Specific Antigen Test: Current Recommendations."